This placement matters. Most remaining microscopic tumor cells sit on the surface of that cavity, and the tiles distribute radiation evenly across it. The seeds emit low-dose therapeutic radiation over several weeks while limiting exposure to healthy tissue, because the radiation dose falls off very rapidly with distance from the tile.

How did patients fare in the trial?

The improved outcomes did not come at the cost of extra toxicity. Serious treatment-related side effects showed no differences between the two groups, and the rate of radiation necrosis — a late risk of radiation treatment for brain metastases in which damaged tissue forms a lesion — was nearly identical between TBRT and SRT patients.

Treatment was also faster. Most TBRT patients completed their cranial radiation in just one day, because the tiles are implanted during surgery itself. Patients needing postoperative SRT faced a median of 32 days to complete treatment. Finishing faster could allow an earlier return to systemic cancer therapies such as immunotherapy or chemotherapy.

"These results are dramatically better than the current alternatives and provide improved patient convenience by getting them over the roadblock of a brain metastasis diagnosis more quickly," said Thomas Beckham, M.D., Ph.D., assistant professor of CNS radiation oncology and trial co-lead.

"At the end of the day, being able to get them over that roadblock and back to managing their cancer overall seems to positively impact more than just their surgical outcome, which is really exciting and something we weren't expecting to this magnitude," Beckham said.

Why does the current standard fall short?

Many patients with advanced solid tumors develop brain metastases, which can significantly affect treatment and prognosis. For patients who need surgery — typically because of larger or symptomatic metastases — the standard approach is surgical resection followed by SRT, a highly focused, high-dose radiation treatment aimed at destroying leftover tumor cells while sparing healthy tissue.

The radiation step is not optional. Without it, microscopic tumor cells left in the surgical cavity cause recurrence 50%–60% of the time.

Yet the standard schedule is hard to deliver. Prior studies show SRT works best within four weeks of surgery, but many patients face post-surgical complications, logistical and scheduling challenges, and interruptions to systemic therapy. Roughly 20% of patients never receive their planned postoperative SRT at all, which compromises their outcomes.

TBRT sidesteps that problem by design: the radiation goes in during the operation, before any scheduling or recovery issues can intervene.

What comes next?

The researchers hope the results will accelerate adoption of TBRT in treatment guidelines and lead to broader clinical use. Future work, they say, can determine how widely TBRT reshapes metastasis care and explore its potential for treating other tumor types.

As with any single trial, the findings are preliminary in the sense that broader adoption will depend on how the results translate across different patient populations and clinical settings. But with a randomized Phase III design, a twelvefold difference in one-year local recurrence, and a survival advantage measured in years, the ROADS data make a strong case that tile-based radiation deserves a place in the standard of care conversation.

Publication details: Jeffrey S. Weinberg et al., "Surgery and tile-based radiation therapy versus surgery and stereotactic radiation for newly diagnosed brain metastases (ROADS): a randomized, open-label, phase 3 trial," Journal of Clinical Oncology (2026). DOI: 10.1200/jco-26-01894